Hemispherian News | Hemispherian awarded NOK 16M grant from the Research Council of Norway
Summary
The companys lead drug candidate, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma, a highly aggressive and most common primary brain cancer, which continues to be one of the highest unmet needs in oncology. The funding awarded is earmarked for the development of Hemispherians promising drug candidates aimed at treating platinum-resistant ovarian cancers, one of the most challenging gynecological malignancies. "We are immensely grateful for this support from the Research Council of Norway," said Zeno Albisser, CEO of Hemispherian. "Hemispherian is an innovative pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX). GLIX compounds target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death.